NO170487C - Analogifremgangsmaate til fremstilling av terapeutisk aktive vannloeselige camptothecin-analoger - Google Patents

Analogifremgangsmaate til fremstilling av terapeutisk aktive vannloeselige camptothecin-analoger

Info

Publication number
NO170487C
NO170487C NO885352A NO885352A NO170487C NO 170487 C NO170487 C NO 170487C NO 885352 A NO885352 A NO 885352A NO 885352 A NO885352 A NO 885352A NO 170487 C NO170487 C NO 170487C
Authority
NO
Norway
Prior art keywords
preparation
alkyl
hydrogen
activated water
camptothecin analogs
Prior art date
Application number
NO885352A
Other languages
English (en)
Norwegian (no)
Other versions
NO885352D0 (no
NO885352L (no
NO170487B (no
Inventor
Jeffrey Charles Boehm
Sidney Michael Hecht
Kenneth George Holden
Randall Keith Johnson
William Dennis Kingsbury
Original Assignee
Smithkline Beckman Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beckman Corp filed Critical Smithkline Beckman Corp
Publication of NO885352D0 publication Critical patent/NO885352D0/no
Publication of NO885352L publication Critical patent/NO885352L/no
Priority to NO912386A priority Critical patent/NO172391C/no
Publication of NO170487B publication Critical patent/NO170487B/no
Publication of NO170487C publication Critical patent/NO170487C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Semiconductor Lasers (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
NO885352A 1987-12-01 1988-11-30 Analogifremgangsmaate til fremstilling av terapeutisk aktive vannloeselige camptothecin-analoger NO170487C (no)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NO912386A NO172391C (no) 1987-12-01 1991-06-19 Mellomprodukt for fremstilling av vannloeselige camptothecin-analoger

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12714887A 1987-12-01 1987-12-01

Publications (4)

Publication Number Publication Date
NO885352D0 NO885352D0 (no) 1988-11-30
NO885352L NO885352L (no) 1989-06-02
NO170487B NO170487B (no) 1992-07-13
NO170487C true NO170487C (no) 1992-10-21

Family

ID=22428545

Family Applications (2)

Application Number Title Priority Date Filing Date
NO885352A NO170487C (no) 1987-12-01 1988-11-30 Analogifremgangsmaate til fremstilling av terapeutisk aktive vannloeselige camptothecin-analoger
NO1998003C NO1998003I1 (no) 1987-12-01 1998-01-15 Topotecan

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO1998003C NO1998003I1 (no) 1987-12-01 1998-01-15 Topotecan

Country Status (25)

Country Link
US (1) US5004758A (fr)
EP (1) EP0321122B1 (fr)
JP (1) JPH0633268B2 (fr)
KR (1) KR930009357B1 (fr)
CN (3) CN1027265C (fr)
AT (1) ATE143368T1 (fr)
AU (1) AU612735B2 (fr)
CA (1) CA1308102C (fr)
CY (1) CY2017A (fr)
DE (2) DE3855575T2 (fr)
DK (1) DK173034B1 (fr)
ES (1) ES2094721T3 (fr)
FI (1) FI89923C (fr)
GR (1) GR3021990T3 (fr)
HK (1) HK81097A (fr)
IE (1) IE74873B1 (fr)
IL (1) IL88517A (fr)
LU (2) LU90026I2 (fr)
MX (1) MX9203744A (fr)
NL (1) NL970017I2 (fr)
NO (2) NO170487C (fr)
NZ (1) NZ227124A (fr)
PT (1) PT89111B (fr)
SG (1) SG66254A1 (fr)
ZA (1) ZA888938B (fr)

Families Citing this family (143)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5053512A (en) * 1987-04-14 1991-10-01 Research Triangle Institute Total synthesis of 20(S) and 20(R)-camptothecin and compthothecin derivatives
US5122526A (en) * 1987-03-31 1992-06-16 Research Triangle Institute Camptothecin and analogs thereof and pharmaceutical compositions and method using them
US5106742A (en) * 1987-03-31 1992-04-21 Wall Monroe E Camptothecin analogs as potent inhibitors of topoisomerase I
US5364858A (en) * 1987-03-31 1994-11-15 Research Triangle Institute Camptothecin analogs as potent inhibitors of topoisomerase I
US5227380A (en) * 1987-03-31 1993-07-13 Research Triangle Institute Pharmaceutical compositions and methods employing camptothecins
US5049668A (en) * 1989-09-15 1991-09-17 Research Triangle Institute 10,11-methylenedioxy-20(RS)-camptothecin analogs
US5122606A (en) * 1987-04-14 1992-06-16 Research Triangle Institute 10,11-methylenedioxy camptothecins
US5180722A (en) * 1987-04-14 1993-01-19 Research Triangle Institute 10,11-methylenedioxy-20(RS)-camptothecin and 10,11-methylenedioxy-20(S)-camptothecin analogs
US5340817A (en) * 1987-04-14 1994-08-23 Research Triangle Institute Method of treating tumors with anti-tumor effective camptothecin compounds
US4939255A (en) * 1987-06-24 1990-07-03 Daiichi Pharmaceutical Co., Ltd. Hexa-cyclic camptothecin derivatives
US5552154A (en) * 1989-11-06 1996-09-03 The Stehlin Foundation For Cancer Research Method for treating cancer with water-insoluble s-camptothecin of the closed lactone ring form and derivatives thereof
JP2684104B2 (ja) * 1990-02-09 1997-12-03 株式会社ヤクルト本社 新規なカンプトテシン誘導体
SK283693B6 (sk) * 1990-09-28 2003-12-02 Smithkline Beecham Corporation Spôsob prípravy kamptotecínu alebo jeho farmaceuticky prijateľnej soli
US5883255A (en) * 1990-10-31 1999-03-16 Smithkline Beecham Corporation Substituted indolizino 1,2-b!quinolinones
AU664172B2 (en) * 1991-02-21 1995-11-09 Smithkline Beecham Corporation Treatment of esophageal cancer
CA2103707C (fr) * 1991-02-21 2003-12-09 Randall Keith Johnson Traitement des carcinomes pulmonaires autres que le cancer pulmonaire a petites cellules
EP0572557B1 (fr) * 1991-02-21 2009-10-07 SmithKline Beecham Corporation Utilisation de topotecan dans la preparation d'un medicament pour le traitement du cancer des ovaires
ATE136898T1 (de) * 1991-10-29 1996-05-15 Glaxo Wellcome Inc Wasserlösliche camptothecinderivate
US5559235A (en) * 1991-10-29 1996-09-24 Glaxo Wellcome Inc. Water soluble camptothecin derivatives
DK0612248T3 (da) * 1991-11-15 2003-12-08 Smithkline Beecham Corp Præparat, der indeholder cisplatin og topotecan som antitumormiddel
AU2394392A (en) * 1991-12-10 1993-07-19 Smithkline Beecham Corporation Treatment of colorectal cancer
US6080751A (en) * 1992-01-14 2000-06-27 The Stehlin Foundation For Cancer Research Method for treating pancreatic cancer in humans with water-insoluble S-camptothecin of the closed lactone ring form and derivatives thereof
US5446047A (en) * 1992-07-23 1995-08-29 Sloan-Kettering Institute For Cancer Research Camptothecin analogues
US5391745A (en) * 1992-07-23 1995-02-21 Sloan-Kettering Institute For Cancer Research Methods of preparation of camptothecin analogs
US5614549A (en) * 1992-08-21 1997-03-25 Enzon, Inc. High molecular weight polymer-based prodrugs
EP0655919A4 (fr) * 1992-08-21 1995-10-18 Dana Farber Cancer Inst Inc Traitement d'infections virales chez l'homme.
US5342947A (en) * 1992-10-09 1994-08-30 Glaxo Inc. Preparation of water soluble camptothecin derivatives
AP9300587A0 (en) * 1992-11-12 1995-05-05 Glaxo Inc Water soluble camptothecin derivatives.
US5674872A (en) * 1993-08-20 1997-10-07 Smithkline Beecham Corporation Treatment of ovarian cancer
AU8052194A (en) * 1993-10-20 1995-05-08 Enzon, Inc. 2'- and/or 7- substituted taxoids
US5880131A (en) * 1993-10-20 1999-03-09 Enzon, Inc. High molecular weight polymer-based prodrugs
US5436243A (en) * 1993-11-17 1995-07-25 Research Triangle Institute Duke University Aminoanthraquinone derivatives to combat multidrug resistance
US5447936A (en) * 1993-12-22 1995-09-05 Bionumerik Pharmaceuticals, Inc. Lactone stable formulation of 10-hydroxy 7-ethyl camptothecin and methods for uses thereof
GB9402934D0 (en) * 1994-02-16 1994-04-06 Erba Carlo Spa Camptothecin derivatives and process for their preparation
US5468754A (en) * 1994-04-19 1995-11-21 Bionumerik Pharmaceuticals, Inc. 11,7 substituted camptothecin derivatives and formulations of 11,7 substituted camptothecin derivatives and methods for uses thereof
US5604233A (en) * 1994-04-28 1997-02-18 Bionumerik Pharmaceuticals, Inc. Lactone stable formulation of 7-ethyl camptothecin and methods for uses thereof
MX9605131A (es) * 1994-04-28 1997-10-31 Bionumerik Pharmaceutical Inc Formulacion estable de lactona de 7-etil-camptotecina y metodo para usar la misma.
US5597829A (en) * 1994-05-09 1997-01-28 Bionumerik Pharmaceuticals, Inc. Lactone stable formulation of camptothecin and methods for uses thereof
US5491237A (en) 1994-05-03 1996-02-13 Glaxo Wellcome Inc. Intermediates in pharmaceutical camptothecin preparation
US5834442A (en) * 1994-07-07 1998-11-10 Barbara Ann Karmanos Cancer Institute Method for inhibiting cancer metastasis by oral administration of soluble modified citrus pectin
US5646159A (en) * 1994-07-20 1997-07-08 Research Triangle Institute Water-soluble esters of camptothecin compounds
US6504029B1 (en) * 1995-04-10 2003-01-07 Daiichi Pharmaceutical Co., Ltd. Condensed-hexacyclic compounds and a process therefor
GB9510716D0 (en) * 1995-05-26 1995-07-19 Pharmacia Spa Substituted camptothecin derivatives and process for their preparation
US5663177A (en) * 1995-05-31 1997-09-02 Smithkline Beecham Corporation Water soluble camptothecin analogs
US5670500A (en) * 1995-05-31 1997-09-23 Smithkline Beecham Corporation Water soluble camptothecin analogs
CA2223484A1 (fr) * 1995-06-07 1996-12-19 Thomas Jefferson University Agents antifongiques et leurs procedes d'identification et d'utlisation
AU7732996A (en) * 1995-11-22 1997-06-11 Research Triangle Institute Camptothecin compounds with combined topoisomerase i inhibition and dna alkylation properties
US6395541B1 (en) 1996-05-23 2002-05-28 The Rockefeller University Methods for the identification of compounds capable of inhibiting HIV-1 viral replication employing murine cell lines expressing human topoisomerase I
IL127800A (en) * 1996-08-19 2005-11-20 Bionumerik Pharmaceuticals Inc Highly lipophilic 7-substituted camptothecin derivatives and pharmaceutical compositions containing them
US6013505A (en) * 1996-10-08 2000-01-11 Smithkline Beecham Corporation Topoisomerase I
US5962303A (en) * 1996-10-15 1999-10-05 Smithkline Beecham Corporation Topoisomerase III
US6025156A (en) * 1996-10-15 2000-02-15 Smithkline Beecham Corporation Topoisomerase III
US6559309B2 (en) 1996-11-01 2003-05-06 Osi Pharmaceuticals, Inc. Preparation of a camptothecin derivative by intramolecular cyclisation
ATE329903T1 (de) * 1997-02-14 2006-07-15 Bionumerik Pharmaceuticals Inc Hochgradig lipophile camptothecin-derivate
US6207673B1 (en) 1997-03-12 2001-03-27 The University Of North Carolina At Chapel Hill Covalent conjugates of topoisomerase I and topoisomerase II inhibitors
ID23424A (id) 1997-05-14 2000-04-20 Bayer Ag Glikokonjugat dari 20(s)-kamptotesin
US6046209A (en) * 1997-05-27 2000-04-04 Smithkline Beecham Corporation Water soluble camptothecin analogs
CA2243363C (fr) * 1997-07-17 2002-01-29 Kuraray Co., Ltd. Procede pour produire des chromanes
US6011042A (en) * 1997-10-10 2000-01-04 Enzon, Inc. Acyl polymeric derivatives of aromatic hydroxyl-containing compounds
US6214821B1 (en) 1998-03-05 2001-04-10 Washington State University Research Foundation Methods and composition for the inhibition of cancer cells
IL141232A0 (en) * 1998-08-05 2002-03-10 Aventis Pharma Sa Use of camptothecin derivatives, with reduced gastrointestinal toxicity
AU775373B2 (en) 1999-10-01 2004-07-29 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
FR2801309B1 (fr) * 1999-11-18 2002-01-04 Adir Nouveaux composes analogues de la camptothecine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6288072B1 (en) * 1999-12-29 2001-09-11 Monroe E. Wall Camptothecin β-alanine esters with topoisomerase I inhibition
BR0108728A (pt) 2000-02-28 2003-12-30 Aventis Pharma Sa Combinação farmacêutica terapêutica, e, método para tratar um c ncer.
US6548488B2 (en) 2000-03-17 2003-04-15 Aventis Pharma S.A. Composition comprising camptothecin or a camptothecin derivative and an alkylating agent for the treatment of cancer
US6545010B2 (en) 2000-03-17 2003-04-08 Aventis Pharma S.A. Composition comprising camptothecin or a camptothecin derivative and a platin derivative for the treatment of cancer
AR027687A1 (es) * 2000-03-22 2003-04-09 Yakult Honsha Kk Procedimiento para preparar camptotecina
US6486320B2 (en) 2000-09-15 2002-11-26 Aventis Pharma S.A. Preparation of camptothecin and of its derivatives
HUP0302629A3 (en) 2000-10-27 2005-05-30 Aventis Pharma Sa Pharmaceutical compositions comprising a combination camptothecin and a stilbene derivative for the treatment of cancer
WO2002040653A2 (fr) * 2000-11-14 2002-05-23 Emerald Biostructures, Inc. Structures et methodes de designation de la topoisomerase i
EP2316468A1 (fr) 2002-02-22 2011-05-04 Shire LLC Système de distribution et méthodes de protection et d'administration de dextroamphetamine
US7462601B2 (en) * 2002-03-26 2008-12-09 Tsutomu Kagiya Ameliorant for chemical treatment of cancer
ITRM20020306A1 (it) * 2002-05-31 2003-12-01 Sigma Tau Ind Farmaceuti Esteri in posizione 20 di camptotecine.
US20040062748A1 (en) 2002-09-30 2004-04-01 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US8129330B2 (en) * 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US7563810B2 (en) * 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
US8034831B2 (en) * 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
WO2004055020A1 (fr) * 2002-12-16 2004-07-01 Council Of Scientific And Industrial Research Procede de preparation directe d'analogues de 5-alcoxy et de 5-acyloxy de camptothecines ou de mappicines cetones
FR2852606A1 (fr) * 2003-03-18 2004-09-24 Inst Nat Sante Rech Med Moyens pour inhiber simultanement l'expression de plusieurs genes impliques dans une pathologie
EP1608660B1 (fr) * 2003-03-31 2007-10-10 Council of Scientific and Industrial Research Procede pour preparer du topotecan a partir de 10-hydroxy-4-(s)-camptothecine
CN100406460C (zh) * 2003-11-10 2008-07-30 中国科学院上海药物研究所 喜树碱的新衍生物、制备方法和用途
AR046579A1 (es) * 2003-11-12 2005-12-14 Smithkline Beecham Corp Compuesto cristalino de topotecan, composicion farmaceutica que lo comprende, procedimiento para prepararlo y su uso para preparar dicha composicion farmaceutica
WO2005087808A2 (fr) 2004-03-05 2005-09-22 Ludwig Institute For Cancer Research Matieres et procedes de constructions de liaison de facteurs de croissance
NZ550430A (en) 2004-04-27 2009-06-26 Wellstat Biologics Corp Cancer treatment using viruses and camptothecins
US20050267141A1 (en) 2004-05-28 2005-12-01 Phytogen Life Sciences Inc. Process to prepare camptothecin derivatives
US20050272757A1 (en) * 2004-06-04 2005-12-08 Phytogen Life Sciences Inc. Process to prepare camptothecin derivatives and novel intermediate and compounds thereof
US7122700B2 (en) * 2004-07-30 2006-10-17 Xerox Corporation Arylamine processes
US20090104254A1 (en) 2004-12-22 2009-04-23 Rutgers, The State University Of New Jersey Controlled Release Hydrogels
WO2012050591A1 (fr) 2010-10-15 2012-04-19 Rutgers, The State University Of New Jersey Formulation d'hydrogel pour une administration dermique et oculaire
JP5475234B2 (ja) 2005-01-21 2014-04-16 アステックス・セラピューティクス・リミテッド 医薬化合物
US20090047365A1 (en) * 2005-02-28 2009-02-19 Eisai R & D Management Co., Ltd. Novel Concomitant Use of Sulfonamide Compound with Anti-Cancer Agent
ATE540698T1 (de) * 2005-07-14 2012-01-15 Wellstat Biologics Corp Krebsbehandlung mit viren, fluoropyrimidinen und camptothecinen
EP1943253A1 (fr) * 2005-10-10 2008-07-16 Cipla Limited Nouvelles formes cristallines
WO2007075492A1 (fr) * 2005-12-16 2007-07-05 Sonus Pharmaceuticals, Inc. Composes anticancereux lipophiles
US7547785B2 (en) 2005-12-26 2009-06-16 Dr. Reddy's Laboratories Limited Process for preparing topotecan
WO2007085370A1 (fr) * 2006-01-25 2007-08-02 Heidelberg Pharma Ag Dérivés d’esters lipidiques de la 9-(dimethylamino)methyl-10-hydroxycamptothecine
CN101033230B (zh) * 2006-03-10 2010-12-08 中国科学院上海药物研究所 一类喜树碱衍生物及其应用
KR101394768B1 (ko) 2006-03-30 2014-05-21 드라이스 파마슈티컬스 아이엔씨 캄토테신-세포 투과 펩티드 결합체 및 이를 포함하는 약학 조성물
US20070259031A1 (en) * 2006-04-26 2007-11-08 The Regents Of The University Of California Compositions and methods for convection enhanced delivery of high molecular weight neurotherapeutics
US20110028536A1 (en) * 2006-08-18 2011-02-03 Gjerset Ruth A Methods and compositions for topoisomerase i modulated tumor suppression
WO2008044041A1 (fr) 2006-10-12 2008-04-17 Astex Therapeutics Limited Combinaisons pharmaceutiques
JP5528807B2 (ja) 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド 複合薬剤
US7977483B2 (en) * 2007-04-11 2011-07-12 Scinopharm Taiwan, Ltd. Process for making topotecan
US20080255175A1 (en) * 2007-04-16 2008-10-16 Lam Marina K Anti-cancer agents, compositions and methods of treating cancers
JP5315337B2 (ja) * 2007-04-19 2013-10-16 シノファーム タイワン，リミテッド トポテカン塩酸塩の結晶形およびその製造方法
US8026249B2 (en) * 2007-09-14 2011-09-27 Deutena Pharmaceuticals, Inc. Deuterium-enriched topotecan
ITMI20072268A1 (it) 2007-12-04 2009-06-05 Antibioticos Spa Polimorfi cristallini di topotecan cloridrato con elevato grado di purezza e metodi per la loro preparazione
EP2280013B1 (fr) * 2008-05-29 2013-07-10 MicroBiopharm Japan Co., Ltd. Procédé de production de dérivé de camptothécine
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
KR20110098849A (ko) * 2008-12-23 2011-09-01 파마셋 인코포레이티드 뉴클레오시드 유사체
SG194404A1 (en) 2008-12-23 2013-11-29 Gilead Pharmasset Llc Synthesis of purine nucleosides
PT2376088T (pt) * 2008-12-23 2017-05-02 Gilead Pharmasset Llc Fosforamidatos de nucleósidos de 2-amino-purina 6-osubstituída
ES2575160T3 (es) 2010-03-15 2016-06-24 The Board Of Trustees Of The University Of Illinois Inhibidores de las interacciones que unen la subunidad alfa de la beta integrina-proteína G
PT2609923T (pt) 2010-03-31 2017-08-30 Gilead Pharmasset Llc Processo para a cristalização de 2-(((s)- (perfluorofenoxi)(fenoxi)fosforil)amino)propanoato de (s)-isopropilo
RU2447076C1 (ru) * 2010-12-09 2012-04-10 Закрытое Акционерное Общество "Фарм-Синтез" Способ получения топотекана
JP6013359B2 (ja) 2010-12-17 2016-10-25 ノバルティス アーゲー 組合せ
WO2012083197A1 (fr) 2010-12-17 2012-06-21 Nektar Therapeutics Conjugués polymères hydrosolubles de topotécan
WO2012087943A2 (fr) 2010-12-20 2012-06-28 The Regents Of The University Of Michigan Inhibiteurs de l'interaction de liaison entre le récepteur du facteur de croissance épidermique et la protéine de choc thermique 90
JP2014504638A (ja) 2011-02-01 2014-02-24 グラクソスミスクライン インテレクチュアル プロパティ リミテッド 組合せ
US10047116B2 (en) 2011-10-03 2018-08-14 Mx Adjuvac Ab Nanoparticles, process for preparation and use thereof as carrier for amphipatic and hydrophobic molecules in fields of medicine including cancer treatment and food related compounds
PL235836B1 (pl) * 2012-10-25 2020-11-02 Inst Chemii Organicznej Polskiej Akademii Nauk Pochodne kamptotecyny, sposób ich otrzymywania i zastosowanie
CN103113381B (zh) * 2013-02-26 2014-12-10 大连理工大学 系列水溶性羟基喜树碱环烷胺醇衍生物及其制法与用途
US9907846B2 (en) 2013-04-01 2018-03-06 Mx Adjuvac Ab Nanoparticles, composed of sterol and saponin from Quillaja saponaria Molina for use in pharmaceutical compositions
WO2016123143A1 (fr) 2015-01-26 2016-08-04 The University Of Chicago Lymphocytes t à récepteur d'antigène chimérique (car) reconnaissant le récepteur il 13rα2 spécifique au cancer
JP7264592B2 (ja) 2015-01-26 2023-04-25 ザ ユニバーシティー オブ シカゴ ＩＬ１３Ｒα２結合剤及び癌治療におけるその使用
US10517961B2 (en) 2015-09-25 2019-12-31 ZY Therapeutics, Inc. Drug formulation based on particulates comprising polysaccharide-vitamin conjugate
ES3057783T3 (en) 2016-03-15 2026-03-04 Oryzon Genomics Sa Combinations of lsd1 inhibitors for use in the treatment of neoplastic diseases
EP3458052B1 (fr) * 2016-05-17 2019-11-06 Scandion Oncology A/S Polythérapie du cancer
CA3071599A1 (fr) 2017-08-07 2019-02-14 Amgen Inc. Traitement du cancer du sein triple negatif ou du cancer colorectal comportant des metastases hepatiques par un anticorps anti-pd-l1 et un virus oncolytique
EP3669890A1 (fr) 2018-12-18 2020-06-24 Croda International PLC Nanoparticules filamenteuses ayant un effet d'adjuvant de vaccin
AU2020241896A1 (en) 2019-03-20 2021-09-23 The Regents Of The University Of California Claudin-6 antibodies and drug conjugates
JP7682797B2 (ja) 2019-03-20 2025-05-26 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア クローディン６二重特異性抗体
US20220160872A1 (en) 2019-04-09 2022-05-26 The Board Of Trustees Of The University Of Illinois Drug Adsorbed Highly Porous Activated Carbon for Enhanced Drug Delivery
AU2020266083A1 (en) 2019-04-30 2021-09-23 Instituto de Medicina Molecular João Lobo Antunes Rank pathway inhibitors in combination with CDK inhibitors
EP3962521A1 (fr) 2019-05-02 2022-03-09 University of Florida Research Foundation, Inc. Compositions pour le traitement de gliome diffus pontique intrinsèque
CA3140904A1 (fr) 2019-06-24 2020-12-30 Amgen Inc. Inhibition de la sirp-gamma pour le traitement du cancer
EP4025206A1 (fr) 2019-09-02 2022-07-13 Institut National de la Santé et de la Recherche Médicale (INSERM) Procédés et compositions pour le traitement d'une maladie associée à une déficience de pax6
MX2022010457A (es) * 2020-02-25 2022-11-16 Mediboston Ltd Derivados de camptotecina y conjugados de esta.
US12521444B2 (en) 2021-02-25 2026-01-13 Fortvita Biologics Limited Anti-HER2 antibody-drug conjugates and uses thereof
US20250295771A1 (en) 2022-05-11 2025-09-25 Celgene Corporation Methods and uses related to t cell therapy and production of same
CN116478174B (zh) * 2022-07-29 2025-09-16 杭州爱科瑞思生物医药有限公司 喜树碱衍生物及其制备方法和应用
CN117281809A (zh) * 2023-03-09 2023-12-26 兰州大学 喜树碱类衍生物在制备治疗膀胱癌药物中的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399282A (en) * 1979-07-10 1983-08-16 Kabushiki Kaisha Yakult Honsha Camptothecin derivatives
US4342776A (en) * 1979-11-05 1982-08-03 Merck & Co., Inc. 4-Substituted-3-hydroxy-3-pyrroline-2,5-dione inhibitors of glycolic acid oxidase
US4473692A (en) * 1981-09-04 1984-09-25 Kabushiki Kaisha Yakult Honsha Camptothecin derivatives and process for preparing same
JPS58134095A (ja) * 1982-02-05 1983-08-10 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
JPS58154582A (ja) * 1982-03-10 1983-09-14 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体およびその製造法
JPS58154584A (ja) * 1982-03-10 1983-09-14 Yakult Honsha Co Ltd ５位ヒドロキシ置換カンプトテシン誘導体の製造法
JPS5951289A (ja) * 1982-09-17 1984-03-24 Yakult Honsha Co Ltd 新規な９−置換−カンプトテシン誘導体
JPS59227884A (ja) * 1983-06-09 1984-12-21 Yakult Honsha Co Ltd 新規な７−ヒドロキシアルキルカンプトテシン誘導体
JPS6019790A (ja) * 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
US4775759A (en) * 1984-11-27 1988-10-04 The United States Of America As Represented By The Department Of Health And Human Services Synthesis and utilization of 17-methyl and 17-cyclopropylmethyl-3,14-dihydroxy-4,5α-epoxy 6β-fluoromorphinans (foxy and cyclofoxy) as (18F)-labeled opioid ligands for position emission transaxial tomography (PETT)
US4820816A (en) * 1985-08-02 1989-04-11 President And Fellows Of Harvard College 3-trifuoromethylsulfonyloxy-substituted 1-carbacephalosporins as intermediates for antibiotics
JPH0615546B2 (ja) * 1986-02-24 1994-03-02 株式会社ヤクルト本社 新規なカンプトテシン誘導体
US4894456A (en) * 1987-03-31 1990-01-16 Research Triangle Institute Synthesis of camptothecin and analogs thereof
JP3431931B2 (ja) * 1992-07-16 2003-07-28 旭電化工業株式会社 銅及び銅合金の表面処理方法

Also Published As

Publication number Publication date
KR890009934A (ko) 1989-08-05
EP0321122A3 (fr) 1990-12-27
GR3021990T3 (en) 1997-03-31
IL88517A (en) 1994-10-07
CN1035380C (zh) 1997-07-09
DE3855575D1 (de) 1996-10-31
US5004758A (en) 1991-04-02
LU90053I2 (fr) 1997-07-01
NL970017I1 (nl) 1997-06-02
MX9203744A (es) 1992-09-01
IE883576L (en) 1989-06-01
NO885352D0 (no) 1988-11-30
PT89111B (pt) 1994-01-31
CN1037574C (zh) 1998-03-04
CN1034724A (zh) 1989-08-16
JPH0633268B2 (ja) 1994-05-02
EP0321122B1 (fr) 1996-09-25
NO885352L (no) 1989-06-02
PT89111A (pt) 1989-12-29
DK663688A (da) 1989-06-02
IL88517A0 (en) 1989-06-30
DK663688D0 (da) 1988-11-28
HK81097A (en) 1997-06-20
DE19775017I2 (de) 2002-11-07
FI89923C (fi) 1993-12-10
NZ227124A (en) 1991-12-23
DE3855575T2 (de) 1997-03-20
ES2094721T3 (es) 1997-02-01
FI89923B (fi) 1993-08-31
EP0321122A2 (fr) 1989-06-21
ATE143368T1 (de) 1996-10-15
AU2639488A (en) 1989-06-01
NO1998003I1 (no) 1998-01-15
CY2017A (en) 1998-02-20
LU90026I2 (fr) 1997-04-22
SG66254A1 (en) 1999-07-20
FI885569A0 (fi) 1988-11-30
NO170487B (no) 1992-07-13
CN1027265C (zh) 1995-01-04
IE74873B1 (en) 1997-08-13
AU612735B2 (en) 1991-07-18
FI885569L (fi) 1989-06-02
JPH01186893A (ja) 1989-07-26
CN1087637A (zh) 1994-06-08
DK173034B1 (da) 1999-11-29
CN1083817A (zh) 1994-03-16
ZA888938B (en) 1990-03-28
NL970017I2 (nl) 1997-09-01
KR930009357B1 (ko) 1993-09-28
CA1308102C (fr) 1992-09-29

Similar Documents

Publication Publication Date Title
NO170487C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive vannloeselige camptothecin-analoger
NO882608L (no) Fremgangsmaate for fremstilling av terapeutisk aktive pyrazolopyridiner.
MX9203550A (es) Derivados de 4-aminoquinolina y su uso como medicamentos.
MY132642A (en) Naphthyridine derivatives
DK162519C (da) Dihydropyridazinonderivater og fremgangsmaade til fremstilling deraf samt farmaceutisk praeparat indeholdende forbindelserne
IL105801A (en) 7-(2-aminoethyl)-benzothiazolones their preparation and pharmaceutical compositions containing them
MY105158A (en) Substituted 4-aminoquinoline derivatives as gastric acid secretion inhibutors.
AU6216886A (en) Substituted 2-cyano-2-phenyl ethyl-amine
EP0186023A3 (fr) Dérivés d'acides biliaires, procédé pour leur préparation et compositions pharmaceutiques les contenant
MX9806229A (es) Derivados de benzo(c)quinolicina, su preparacion y uso como inhibidores de la 5alfa-reductasas.
NZ216334A (en) Spiro imidazolone derivatives and pharmaceutical composition
ATE38982T1 (de) Guanidinmethylcyclohexancarbonsaeure-derivate, verfahren zur herstellung und pharmazeutische mittel.
GR3002560T3 (en) 2-selenomethyl-1, 4-dihydropyridines, a process for the preparation thereof and pharmaceutical compositions containing them
GB1471546A (en) 1-acyl-4-substituted alkyl-piperazine or homopiperazine derivatives nad process for preparation thereof

Legal Events

Date Code Title Description
MK1K Patent expired

Name of requester: C/O ADVOKATFIRMAET SELMER DA